CA-LINKSYS
24.5.2022 17:02:58 CEST | Business Wire | Press release
Linksys , a global leader in home and business WiFi networking solutions, today announced two new WiFi 6 mesh systems designed to deliver peak wireless performance for all at-home needs including remote working, streaming content, multi-user gaming and more. The Linksys Hydra 6 and Linksys Atlas 6 are Linksys’ newest entry-level dual-band products in the company's family of WiFi 6 mesh systems and come at the most affordable prices to date for the brand.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220524005310/en/
“There is an increased need for wireless connectivity that can handle the influx of devices on home networks, and deliver reliable, secure and private connections,” said Alan Cohen, VP of Marketing and Head of Product at Linksys. “Our mission is to connect everyone securely and through the launch of these systems, we provide our customers with two new options for fast speed, coverage, and connectivity at an affordable price point.”
Linksys Atlas 6 – Our Most Affordable WiFi 6 Mesh System to Date
The Linksys Atlas 6 is the newest whole-home mesh system in Linksys’ portfolio of products. Speed and performance at an affordable price, the Linksys Atlas 6 is ideal for hybrid work, online gaming, 4K UHD streaming, and more. The dual-band router works best with internet service plans up to a gigabit. Each Node has three 1Gbps Ethernet LAN ports for connecting wired devices to wireless networks and provides access to 160MHz channels for superfast wireless connections.
The Linksys Atlas 6 is available in three configurations. The 1-pack supports up to 25 devices and covers ~2,000 square feet, the 2-pack supports up to 50 devices and covers ~4,000 square feet, and the 3-pack supports up to 75 devices and up to ~6,000 square feet.
Linksys Hydra 6 – Dramatically Faster, Robust, and Reliable Connectivity
The Linksys Hydra 6 delivers high-speed wireless data for up to 25 devices over 2,000 square feet. The Linksys Hydra 6 WiFi 6 dual-band mesh router delivers dramatically faster, robust, and reliable wireless connections. Ideal for super smooth 4K UHD streaming, video conferencing, online gaming, and more. The router works best with internet service plans up to a gigabit. It provides 160 MHz channels for superfast wireless connections and has four 1 GbE Ethernet ports to connect wired devices such as gaming devices, television, DVR, and more to the wireless network.
Additional Features and Benefits for the Linksys Atlas 6 and Hydra 6
- Fast to set up. Easy to manage. – The Linksys App makes it simple to set up your WiFi network and you can control and monitor your WiFi from anywhere.
- Linksys Intelligent Mesh™ Technology – Dynamically optimize speeds and maximize the use of all bands to reduce congestion, latency and buffering.
- Security and privacy you can trust – Protect your home with automatic software updates so your network is always secure and up to date. Parental controls and separate guest networks keep devices safe.
- Peace of mind – Linksys products pass 25 quality tests, are backed by a 3-year warranty, and have 24/7 tech support.
- Grow as needed – When your family, home and needs grow, your WiFi should grow with you. Add more nodes to expand coverage for stronger connection and to handle more devices as needed.
- Robust. Stable. Reliable. – Built with the Qualcomm® Immersive Home 214 Platform users can expect great connectivity throughout the home.
Availability and Imagery
The Linksys Hydra 6 will be available beginning early summer in the US for MSRP $179.99 on Linksys.com and in select retailers; global availability to follow in the second half of 2022.
The Linksys Atlas 6 will be available beginning early summer in the US for MSRP $149.99 (1-pack), $279.99 (2-pack), and $349.99 (3-pack) on Linksys.com; global availability to follow in the second half of 2022.
Images of the Atlas 6 and Hydra 6 can be found here .
About Linksys
At Linksys, we strive to build the world’s most reliable, innovative, future-ready wireless technologies that can securely connect every person and everything, effortlessly. Founded in 1988, Linksys has since established itself as a premier networking brand. Today, Linksys hardware products, software, and services are sold in 64 countries worldwide, ranging from home routers and mesh systems to business access points and switches. Recently, Linksys expanded into education and enterprise through its partnership with Fortinet, the leader in enterprise-grade security. Linksys. For every connection.
Qualcomm is a trademark or registered trademark of Qualcomm Incorporated.
Qualcomm Immersive Home 214 Platform is a product of Qualcomm Technologies, Inc. and/or its subsidiaries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220524005310/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom